article
Raman Spectroscopy: In-Depth Focus 2014
Sulaf Assi discusses the investigation of medicine quality using handheld Raman spectroscopy, a look at Raman hyperspectral imaging, plus Raman roundtable...
List view / Grid view
Pfizer
news
Pfizer completes acquisition of InnoPharma
26 September 2014 | By Pfizer
Pfizer Inc. announced that it has completed its acquisition of the pharmaceutical development company, InnoPharma, Inc., following receipt of United States regulatory approval from all government authorities required by the agreement and other closing conditions...
news
Pfizer and Protalix BioTherapeutics announce FDA approval of pediatric Indication for ELELYSO™ (taliglucerase alfa) for injection
29 August 2014 | By Pfizer
...for intravenous use for the treatment of type 1 Gaucher disease.
news
Pfizer’s investigational vaccine candidate for Clostridium difficile receives U.S. Food and Drug Administration Fast Track designation
28 August 2014 | By Pfizer
Pfizer Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation to the company’s investigational Clostridium difficile vaccine candidate (PF-06425090). Currently in Phase 2 clinical development, the vaccine candidate is designed to prevent C...
news
Pfizer and Merck to collaborate on study evaluating novel anti-cancer combination regimen
27 August 2014 | By Pfizer
Pfizer Inc. and Merck & Co. Inc. through a subsidiary, announced that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib (XALKORI®) with Merck’s investigational anti-PD-1 antibody pembrolizumab...
news
Pfizer announces submission of palbociclib New Drug Application to the FDA
19 August 2014 | By Pfizer
Pfizer Inc. announced it has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration for palbociclib...
news
Pfizer announces FDA acceptance of and priority review designation for biologics license application for investigational meningococcal B vaccine
15 August 2014 | By Pfizer
Pfizer Inc. announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for bivalent recombinant LP2086...
news
Advisory committee on Immunization Practices votes to recommend Pfizer’s Prevnar 13® vaccine in adults aged 65 years and older
14 August 2014 | By Pfizer
Pfizer Inc. announced that the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to recommend Prevnar 13®...
news
European Medicines Agency accepts application seeking new indication for Prevenar 13®1 for prevention of pneumococcal pneumonia in adults
8 August 2014 | By Pfizer
Application includes data from Pfizer’s community-acquired pneumonia immunization trial in adults (CAPiTA)...
news
Pfizer enters into agreement to acquire Baxter’s portfolio of marketed vaccines
30 July 2014 | By Pfizer
Pfizer Inc. announced that it has entered into a definitive agreement to acquire Baxter International Inc.’s portfolio of marketed vaccines for $635 million...
news
Bristol-Myers Squibb and Pfizer announce enrollment of first patient in Phase IV EMANATE trial to assess effectiveness and safety of Eliquis® (apixaban) in patients with NVAF undergoing cardioversion
18 July 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced that the first patient has been enrolled into a Phase IV clinical trial called EMANATE assessing the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation undergoing cardioversion...
news
Pfizer announces positive top-line results from Phase 3 study of NONACOG ALFA (BeneFIX®) once-weekly prophylaxis for hemophilia B
17 July 2014 | By Pfizer
Pfizer Inc. announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX® Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B...
news
CliniWorks forms a strategic alliance with Pfizer to develop a population health management platform with advanced analytics and patient care capabilities
10 July 2014 | By Pfizer
CliniWorks announced a strategic alliance between its Israeli subsidiary CliniWorks (Israel) Ltd. and Pfizer Inc. to jointly advance the parties’ respective capabilities in working with healthcare provider organizations to identify and close clinical or quality gaps to improve population health...
news
Pfizer Inc. receives kosher certification for Elelyso™ (taliglucerase alfa) for injection, for the treatment of Type 1 Gaucher disease
2 July 2014 | By Pfizer
Pfizer Inc. announced that the Orthodox Union has granted kosher certification to ELELYSO™ (taliglucerase alfa) for injection, an enzyme replacement therapy for the long-term treatment of adults with a confirmed diagnosis of Type 1 Gaucher disease...
news
Pfizer declares 26-cent third-quarter 2014 dividend
27 June 2014 | By Pfizer
The board of directors of Pfizer Inc. declared a 26-cent third-quarter 2014 dividend on the company’s common stock...
